{"id":"https://openalex.org/W2048929025","doi":"https://doi.org/10.1177/0091270008323750","title":"Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus","display_name":"Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus","alternate_titles":[],"publication_year":2008,"publication_date":"2008-12-01","ids":{"openalex":"https://openalex.org/W2048929025","doi":"https://doi.org/10.1177/0091270008323750","mag":"2048929025","pmid":"https://pubmed.ncbi.nlm.nih.gov/19047364"},"language":"en","primary_location":{"id":"doi:10.1177/0091270008323750","doi":"https://doi.org/10.1177/0091270008323750","is_oa":false,"landing_page_url":"https://doi.org/10.1177/0091270008323750","pdf_url":null,"source":{"id":"https://openalex.org/S146237847","display_name":"The Journal of Clinical Pharmacology","issn_l":"0021-9754","issn":["0021-9754","0091-2700","0095-9863","1552-4604","2375-0839","2375-0928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Pharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2048929025"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5079794570","display_name":"Prajakti A. Kothare","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Prajakti A. Kothare","raw_affiliation_strings":["Global PK/PD and Trial Simulations, Eli Lilly and Company, Indianapolis, IN 46285, USA. kotharep@lilly.com","Eli Lilly and Company Indianapolis Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global PK/PD and Trial Simulations, Eli Lilly and Company, Indianapolis, IN 46285, USA. kotharep@lilly.com","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"Eli Lilly and Company Indianapolis Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064098013","display_name":"Helle Linnebjerg","orcid":"https://orcid.org/0000-0001-5849-921X","observed_orcids":["https://orcid.org/0000-0001-5849-921X"]},"institutions":[{"id":"https://openalex.org/I4210095227","display_name":"Eli Lilly (United Kingdom)","ror":"https://ror.org/00psab413","country_code":"GB","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210095227"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Helle Linnebjerg","raw_affiliation_strings":["Eli Lilly and Company, Windlesham, Surrey, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Windlesham, Surrey, United Kingdom","institution_ids":["https://openalex.org/I4210095227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014966690","display_name":"Yoshitaka Isaka","orcid":"https://orcid.org/0000-0002-0820-7167","observed_orcids":["https://orcid.org/0000-0002-0820-7167","https://orcid.org/0009-0003-6787-655X"]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yoshitaka Isaka","raw_affiliation_strings":["Eli Lilly and Company, Kobe, Japan","Eli Lilly & Company, Kobe, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Kobe, Japan","institution_ids":["https://openalex.org/I4210108315"]},{"raw_affiliation_string":"Eli Lilly & Company, Kobe, Japan","institution_ids":["https://openalex.org/I4210108315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011080430","display_name":"Kazunori Uenaka","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kazunori Uenaka","raw_affiliation_strings":["Eli Lilly and Company, Kobe, Japan","Eli Lilly & Company, Kobe, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Kobe, Japan","institution_ids":["https://openalex.org/I4210108315"]},{"raw_affiliation_string":"Eli Lilly & Company, Kobe, Japan","institution_ids":["https://openalex.org/I4210108315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081811997","display_name":"Ayuko Yamamura","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ayuko Yamamura","raw_affiliation_strings":["Eli Lilly and Company, Kobe, Japan","Eli Lilly & Company, Kobe, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Kobe, Japan","institution_ids":["https://openalex.org/I4210108315"]},{"raw_affiliation_string":"Eli Lilly & Company, Kobe, Japan","institution_ids":["https://openalex.org/I4210108315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109241230","display_name":"Kwee Poo Yeo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165932596","display_name":"National University of Singapore","ror":"https://ror.org/01tgyzw49","country_code":"SG","type":"education","lineage":["https://openalex.org/I165932596"]}],"countries":["SG"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kwee Poo Yeo","raw_affiliation_strings":["Lilly-NUS Centre for Clinical Pharmacology, Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly-NUS Centre for Clinical Pharmacology, Singapore","institution_ids":["https://openalex.org/I165932596"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022493856","display_name":"Amparo de la Pe\u00f1a","orcid":"https://orcid.org/0009-0009-6341-4933","observed_orcids":["https://orcid.org/0009-0009-6341-4933"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Amparo de la Pe\u00f1a","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056688721","display_name":"Choo Hua Teng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165932596","display_name":"National University of Singapore","ror":"https://ror.org/01tgyzw49","country_code":"SG","type":"education","lineage":["https://openalex.org/I165932596"]}],"countries":["SG"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Choo Hua Teng","raw_affiliation_strings":["Lilly-NUS Centre for Clinical Pharmacology, Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly-NUS Centre for Clinical Pharmacology, Singapore","institution_ids":["https://openalex.org/I165932596"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058443646","display_name":"Kenneth F. Mace","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kenneth Mace","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083503351","display_name":"Mark S. Fineman","orcid":"https://orcid.org/0000-0002-9883-6847","observed_orcids":["https://orcid.org/0000-0002-9883-6847"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mark Fineman","raw_affiliation_strings":["Amylin Pharmaceuticals, Inc, San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amylin Pharmaceuticals, Inc, San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108205603","display_name":"Hirofumi Shigeta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hirofumi Shigeta","raw_affiliation_strings":["Eli Lilly and Company, Kobe, Japan","Eli Lilly & Company, Kobe, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Kobe, Japan","institution_ids":["https://openalex.org/I4210108315"]},{"raw_affiliation_string":"Eli Lilly & Company, Kobe, Japan","institution_ids":["https://openalex.org/I4210108315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110346494","display_name":"Yukikuni Sakata","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yukikuni Sakata","raw_affiliation_strings":["PS Clinic, Fukuoka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PS Clinic, Fukuoka, Japan","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108452568","display_name":"Shin Irie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115738","display_name":"SOUSEIKAI Global Clinical Research Center","ror":"https://ror.org/022bpxw56","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210115738"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Shin Irie","raw_affiliation_strings":["Kyushu Clinical Pharmacology Research Clinic, Fukuoka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kyushu Clinical Pharmacology Research Clinic, Fukuoka, Japan","institution_ids":["https://openalex.org/I4210115738"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5079794570"],"corresponding_institution_ids":["https://openalex.org/I168537998"],"apc_list":{"value":4150,"currency":"USD","value_usd":4150},"apc_paid":null,"fwci":2.51,"has_fulltext":false,"cited_by_count":64,"citation_normalized_percentile":{"value":0.89310313,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"48","issue":"12","first_page":"1389","last_page":"1399"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/exenatide","display_name":"exenatide","score":1.0},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9639999866485596},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9779999852180481},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9990000128746033},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.7369999885559082},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.6660000085830688},{"id":"https://openalex.org/keywords/postprandial-blood-glucose","display_name":"postprandial blood glucose","score":0.8159999847412109},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.6790000200271606},{"id":"https://openalex.org/keywords/emax-model","display_name":"Emax model","score":0.9020000100135803},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.7319999933242798},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.8920000195503235}],"concepts":[{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.9731302261352539},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.9096436500549316},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8137308359146118},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7607616186141968},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7226241230964661},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7061684131622314},{"id":"https://openalex.org/C2778199505","wikidata":"https://www.wikidata.org/wiki/Q2992990","display_name":"Postprandial","level":3,"score":0.5348160862922668},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5243985056877136},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5218937993049622},{"id":"https://openalex.org/C2780473172","wikidata":"https://www.wikidata.org/wiki/Q5572518","display_name":"Glycemic","level":3,"score":0.5007479190826416},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.48584625124931335},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.46387895941734314},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4447833299636841},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3295339345932007},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.32737594842910767},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.22134742140769958},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.19366708397865295},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077270","descriptor_name":"Exenatide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000208","qualifier_name":"ethnology","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004797","descriptor_name":"Enzyme-Linked Immunosorbent Assay","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005934","descriptor_name":"Glucagon","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009325","descriptor_name":"Nausea","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014839","descriptor_name":"Vomiting","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D016037","descriptor_name":"Single-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D044466","descriptor_name":"Asian People","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1177/0091270008323750","doi":"https://doi.org/10.1177/0091270008323750","is_oa":false,"landing_page_url":"https://doi.org/10.1177/0091270008323750","pdf_url":null,"source":{"id":"https://openalex.org/S146237847","display_name":"The Journal of Clinical Pharmacology","issn_l":"0021-9754","issn":["0021-9754","0091-2700","0095-9863","1552-4604","2375-0839","2375-0928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:19047364","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19047364","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":43,"referenced_works":["https://openalex.org/W4206524","https://openalex.org/W43308025","https://openalex.org/W201798488","https://openalex.org/W1003041909","https://openalex.org/W1507814807","https://openalex.org/W1910418518","https://openalex.org/W1964478407","https://openalex.org/W1965358308","https://openalex.org/W1972086236","https://openalex.org/W1972204120","https://openalex.org/W1973771269","https://openalex.org/W1984740259","https://openalex.org/W1986085856","https://openalex.org/W2001097346","https://openalex.org/W2011499650","https://openalex.org/W2044160793","https://openalex.org/W2062883844","https://openalex.org/W2069150029","https://openalex.org/W2070710390","https://openalex.org/W2079023387","https://openalex.org/W2094081978","https://openalex.org/W2101613382","https://openalex.org/W2101718966","https://openalex.org/W2101812366","https://openalex.org/W2103266155","https://openalex.org/W2106274126","https://openalex.org/W2108771199","https://openalex.org/W2114102308","https://openalex.org/W2115707749","https://openalex.org/W2121894019","https://openalex.org/W2124893121","https://openalex.org/W2125626003","https://openalex.org/W2126115073","https://openalex.org/W2128167237","https://openalex.org/W2132766113","https://openalex.org/W2137805490","https://openalex.org/W2142051176","https://openalex.org/W2149967041","https://openalex.org/W2162934281","https://openalex.org/W2337454357","https://openalex.org/W2344620176","https://openalex.org/W2634243099","https://openalex.org/W2911057706"],"related_works":["https://openalex.org/W1981012218","https://openalex.org/W2344620176","https://openalex.org/W2320295223","https://openalex.org/W2045753702","https://openalex.org/W2008132861","https://openalex.org/W2014468166","https://openalex.org/W2021726283","https://openalex.org/W1511301354","https://openalex.org/W1484868350","https://openalex.org/W1584971378"],"abstract_inverted_index":{"In":[0],"this":[1],"single-blind,":[2],"parallel,":[3],"placebo-controlled":[4],"study,":[5],"the":[6,113],"pharmacokinetics,":[7],"pharmacodynamics,":[8],"tolerability,":[9],"and":[10,31,68,72,87,92,98,102,147,178,200,204],"safety":[11],"of":[12,115,144,150],"subcutaneous":[13],"exenatide":[14,35,57,161,207],"were":[15,26,121,174,191],"evaluated":[16],"in":[17,125,166,215],"40":[18],"Japanese":[19,216],"patients":[20,54,217],"with":[21,44,140,155,171,218],"type":[22,219],"2":[23,220],"diabetes.":[24,221],"Patients":[25],"allocated":[27],"to":[28,33,78,83,133,158],"4":[29],"groups":[30,85,96],"randomized":[32],"receive":[34],"(n":[36,41],"=":[37,42],"8/group)":[38],"or":[39,62,70,123],"placebo":[40,47,71],"2/group),":[43],"all":[45],"receiving":[46],"on":[48,75,90,112,198],"day":[49,52,116],"1.":[50],"On":[51,80],"2,":[53],"received":[55,100],"single-dose":[56],"(2.5":[58],"microg":[59,64,94,104,190,206],"[group":[60],"A]":[61],"5":[63,93,203],"[groups":[65],"B,":[66],"C,":[67],"D])":[69],"then":[73],"bid":[74],"days":[76,81],"3":[77],"5.":[79],"6":[82],"10,":[84],"A":[86],"B":[88],"continued":[89],"2.5":[91,189],"bid;":[95],"C":[97],"D":[99],"10":[101,134,159,177,205],"15":[103,179],"bid,":[105],"respectively.":[106],"The":[107],"last":[108],"dose":[109],"was":[110,128,137],"given":[111],"morning":[114],"10.":[117],"All":[118],"adverse":[119],"events":[120],"mild":[122],"moderate":[124],"severity.":[126],"Exenatide":[127,136],"generally":[129],"well":[130,138],"tolerated":[131],"up":[132],"microg.":[135,180],"absorbed":[139],"a":[141,167],"median":[142],"t(max)":[143],"1.5":[145],"hours":[146],"mean":[148],"t((1/2))":[149],"1.6":[151],"hours;":[152],"exposure":[153],"increased":[154],"dose.":[156],"Up":[157],"microg,":[160],"reduced":[162],"postprandial":[163],"glucose":[164],"concentrations":[165],"dose-dependent":[168],"fashion":[169],"compared":[170],"placebo;":[172],"decreases":[173],"similar":[175],"for":[176,193,211],"An":[181],"E(max)":[182],"model":[183],"demonstrated":[184],"that":[185],"doses":[186],"higher":[187],"than":[188],"necessary":[192],"adequate":[194],"glycemic":[195],"response.":[196],"Based":[197],"tolerability":[199],"pharmacokinetic/pharmacodynamic":[201],"relationships,":[202],"may":[208],"be":[209],"considered":[210],"further":[212],"clinical":[213],"development":[214]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2048929025","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":4},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":7}],"updated_date":"2026-11-18T13:11:19.462570","created_date":"2016-06-24T00:00:00"}
